Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells

Cancer Research

Volumn 62, Issue 23, 2002, Pages 6916-6923

  Hui, Rina ^a,b   Finney, Georgina L ^a   Carroll, Jason S ^a   Lee, Christine S L ^a   Musgrove, Elizabeth A ^a   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLIN D1; CYCLIN E; FULVESTRANT; PHOSPHOTRANSFERASE; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; S PHASE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0036897326     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330. 1995.
2. 1 Cyclins. Cell, 73: 1059-1065, 1993.
3. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
4. Resnitzky, D., Gossen, M., Bujard, H., and Reed, S. I. Acceleration of the G I/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol., 14: 1669-1679, 1994.
5. Bortner, D. M., and Rosenberg, M. P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol., 17: 453-459, 1997.
6. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.
7. Buckley, M. F., Sweeney, K. J., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
8. Nielsen, N. H., Arnerlov, C., Emdin, S. O., and Landberg, G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br. J. Cancer, 74: 874-880, 1996.
9. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27kip 1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
10. Kenny, F. S., Hui, R., Musgrove, E. A., Gee, J. M., Blamey, R. W., Nicholson, R. I., Sutherland, R. L., and Robertson, J. F. R. Overexpression of Cyclin D1 mRNA predicts for poor prognosis in oestrogen receptor positive breast cancer. Clin. Cancer Res., 5: 2069-2076, 1999.
11. McIntosh, G. G., Anderson, J. J., Milton, I., Steward, M., Parr, A. H., Thomas, M. D., Henry, J. A., Angus, B., Lennard, T. W., and Horne, C. H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11: 885-891, 1995.
12. Gillett, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., and Barnes, D. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer, 69: 92-99, 1996.
13. Pelosio, P., Barbareschi, M., Bonoldi, E., Marchetti, A., Verderio, P., Caffo, O., Bevilacqua, P., Boracchi, P., Buttitta, F., Barbazza, R., Dalla Palma, P., and Gasparini, G. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann. Oncol., 7: 695-703, 1996.
14. Michalides, R., Hageman, P., Vantinteren, H., Houben, L., Wientjens, E., Klompmaker, R., and Peterse, J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 73: 728-734, 1996.
15. Hui, R., Cornish, A. L., McClelland, R. A., Robertson, J. F. R., Blamey, R. W., Musgrove, E. A., Nicholson, R. I., and Sutherland, R. L. Cyclin D1 and estrogen receptor mRNA expression are positively correlated in primary breast cancer. Clin. Cancer Res., 2: 923-928, 1996.
16. Seshadri, R., Lee, C. S. L., Hui, R., McCaul, K., Horsfall, D. J., and Sutherland, R. L. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin. Cancer Res., 2: 1177-1184, 1996.
17. Musgrove, E. A., Hamilton, J. A., Lee, C. S., Sweeney, K. J., Watts, C. K., and Sutherland, R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol., 13: 3577-3587, 1993.
18. Watts, C. K. W., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
19. Wilcken, N. R. C., Prall, O. W. J., Musgrove, E. A., and Sutherland, R. L. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res., 3: 849-854, 1997.
20. Pacilio, C., Germano, D., Addeo, R., Altucci, L., Petrizzi, V. B., Cancemi, M., Cicatiello, L., Salzano, S., Lallemand, F., Michalides, R., Bresciani, F., and Weisz, A. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res., 58: 871-876, 1998.
21. Keyomarsi, K., and Herliczek, T. W. The role of cyclin E in cell proliferation, development and cancer. Prog. Cell Cycle Res., 3: 171-191, 1997.
22. Nielsen, N. H., Emdin, S. O., Cajander, J., and Landberg, G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene, 14: 295-304, 1997.
23. Geng, Y., Whoriskey, W., Park, M. Y., Bronson, R. T., Medema, R. H., Li, T., Weinberg, R. A., and Sicinski, P. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell, 97: 767-777, 1999.
24. Dhillon, N. K., and Mudryj, M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene, 21: 4626-4634, 2002.
25. Sutherland, R. L., Hall, R. E., and Taylor, I. W. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res., 43: 3998-4006, 1983.
26. Prall O. W. J., Rogan, E. M., Musgrove, E. A., Watts, C. K. W., and Sutherland, R. L. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell. Biol., 18: 4499-4508, 1998.
27. Musgrove, E. A., Lee, C. S., Buckley, M. F., and Sutherland, R. L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994.
28. Harlow, E., and Lane, D. Antibodies. A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1988.
29. Coats, S., Flanagan, W. M., Nourse, J., and Roberts, J. M. Requirement of p27Kipl for restriction point control of the fibroblast cell cycle. Science (Wash. DC), 272: 877-880, 1996.
30. Carroll, J. S., Prall, O. W. J., Musgrove, E. A., and Sutherland, R. L. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J. Biol. Chem., 275: 38221-38229, 2000.
31. Cariou, S., Donovan, J. C. H., Flanagan, W. M., Milic, A., Bhattacharya, N., and Slingerland, J. M. Down-regulation of p21WAFI/CIPI or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. USA. 97: 9042-9046, 2000.
32. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet. 352: 930-942, 1998.
33. Jordan, V. C., and Morrow, M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocr. Rev., 20: 253-278, 1999.
34. Jordan, V. C., and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev., 11: 578-610, 1990.
35. Foster, J. S., and Wimalasena, J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol., 10: 488-498, 1996.
36. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
37. Planas-Silva, M. D., and Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol., 17: 4059-4069, 1997.
38. Miuse-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., and Rosen, N. Cyclin D1 expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem., 273: 29864-29872, 1998.
39. Russell, A., Thompson, A., Hendley, J., Trute, L., Armes, J., and Germain, D. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene, 18: 1983-1991, 1999.
40. Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12: 3499-3511, 1998.
41. Ohtsubo, M., and Roberts, J. M. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science (Wash. DC), 259: 1908-1912, 1993.
42. Wimmel, A., Lucibello, F. C., Sewing, A., Adolph, S., and Muller, R. Inducible acceleration of G1 progression through tetracycline-regulated expression of human cyclin E. Oncogene. 9: 995-997, 1994.
43. Resnitzky, D., and Reed, S. I. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol. Cell. Biol., 15: 3463-3469, 1995.
44. Gray-Bablin, J., Zaldive, J., Fox, M. P., Knickerbocker, C. J., DeCaprio, J. A., and Keyomarsi, K. Cyclin E, a redundant cyclin in breast cancer. Proc. Natl. Acad. Sci. USA, 93: 15215-15220, 1996.
45. Santen, R. J. Clinical use of aromatase inhibitors in human breast carcinoma. J. Biochem. Mol. Biol., 40: 247-253, 1991.
46. Lonning, P. E. Pharmacology of new aromatase inhibitors. Breast. 5: 206-208, 1996.
47. Szymczak, J., Milewicz, A., Thijssen, J. H. H., Blankenstein, M. A., and Daroszewski, J. Concentration of sex steroids in adipose tissue after menopause. Steroids. 63: 319-321, 1998.
48. Gill, P. G., Gebski, V., Snyder, R., Burns, I., Levi, J., Byrne, M., and Coates, A. Randomised comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann. Oncol., 4: 741-744, 1993.
49. Castiglione-Gertsch, M., Pampallona, S., Varini, M., Cavalli, F., Brunner, K., Senn, H. J., Goldhirsch, A., and Metzger, U. Primary endocrine therapy for breast cancer: To start with tamoxifen or with medroxyprogesterone acetate? Ann. Oncol., 4: 735-740, 1993.
50. Goss, P. E., and Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol., 19: 881-894, 2001.
51. Kip1 association with cyclin E-Cdk2. J. Biol. Chem., 276: 47675-47683, 2001.
52. Tonetti, D. A., and Jordan, V. C. Possible mechanisms in the emergence of tamoxifen resistant breast cancer. Anticancer Drugs, 6: 498-507, 1995.
53. Lum, S. S., Woltering, E. A., Fletcher, W. S., and Pommier, R. F. Changes in serum estrogen levels in women during tamoxifen therapy. Am. J. Surg., 173: 399-402, 1997.